Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2017, Article ID 3708250, 7 pages
https://doi.org/10.1155/2017/3708250
Research Article

Methotrexate Reduced TNF Bioactivity in Rheumatoid Arthritis Patients Treated with Infliximab

1Department of Rheumatology, CHU Saint-Etienne, Saint-Etienne, France
2Immunology and Immunomonitoring Department, CHU de Saint-Etienne, Saint-Etienne, France
3INSERM 1059/SAINBIOSE, Université Jean Monet, Université de Lyon, Saint-Etienne, France

Correspondence should be addressed to Hubert Marotte; rf.enneite-ts-uhc@ettoram.trebuh

Received 12 October 2016; Accepted 6 February 2017; Published 2 March 2017

Academic Editor: Ronald Gladue

Copyright © 2017 Delphine Dénarié et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Maini, E. W. St Clair, F. Breedveld et al., “Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial,” Lancet, vol. 354, no. 9194, pp. 1932–1939, 1999. View at Publisher · View at Google Scholar · View at Scopus
  2. J. S. Smolen, F. C. Breedveld, G. R. Burmester et al., “Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force,” British Journal of Sports Medicine, vol. 75, pp. 3–15, 2016. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Rubbert-Roth and A. Finckh, “Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review,” Arthritis Research and Therapy, vol. 11, supplement 1, article S1, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Marotte and P. Miossec, “Biomarkers for prediction of TNFα blockers response in rheumatoid arthritis,” Joint Bone Spine, vol. 77, no. 4, pp. 297–305, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. P. P. Tak, “A personalized medicine approach to biologic treatment of rheumatoid arthritis: a preliminary treatment algorithm,” Rheumatology, vol. 51, no. 4, pp. 600–609, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. H. Marotte, W. Maslinski, and P. Miossec, “Circulating tumour necrosis factor-alpha bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response,” Arthritis Research & Therapy, vol. 7, no. 1, pp. R149–R155, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Alessandri, R. Scrivo, F. R. Spinelli et al., “Autoantibody production in anti-TNF-α-treated patients,” Annals of the New York Academy of Sciences, vol. 1110, pp. 319–329, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Finckh, J. Dudler, F. Wermelinger et al., “Influence of anti-infliximab antibodies and residual infliximab concentrations on the occurrence of acquired drug resistance to infliximab in rheumatoid arthritis patients,” Joint Bone Spine, vol. 77, no. 4, pp. 313–318, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Paul, E. Del Tedesco, H. Marotte et al., “Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study,” Inflammatory Bowel Diseases, vol. 19, no. 12, pp. 2568–2576, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. X. Roblin, H. Marotte, M. Leclerc et al., “Combination of C-reactive protein, infliximab trough levels, and stable but not transient antibodies to infliximab are associated with loss of response to infliximab in inflammatory bowel disease,” Journal of Crohn's and Colitis, vol. 9, no. 7, pp. 525–531, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Rinaudo-Gaujous, X. Roblin, H. Marotte, and S. Paul, “The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region,” Annals of the Rheumatic Diseases, vol. 74, no. 8, article no. e41, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. F. Chopin, P. Garnero, A. Le Henanff et al., “Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 67, no. 3, pp. 353–357, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. A. M. van Gestel, M. L. L. Prevoo, M. A. van 'T Hof, M. H. van Rijswijk, L. B. A. van De Putte, and P. L. C. M. van Riel, “Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis,” Arthritis and Rheumatism, vol. 39, no. 1, pp. 34–40, 1996. View at Publisher · View at Google Scholar · View at Scopus
  14. H. Marotte, W. Maslinski, and P. Miossec, “Circulating tumour necrosis factor-α bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response,” Arthritis research & therapy, vol. 7, Article ID R149, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. E. W. St Clair, C. L. Wagner, A. A. Fasanmade et al., “The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial,” Arthritis and Rheumatism, vol. 46, no. 6, pp. 1451–1459, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. E. Ducourau, D. Mulleman, G. Paintaud et al., “Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases,” Arthritis Research and Therapy, vol. 13, no. 3, article no. R105, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. R. N. Maini, F. C. Breedveld, J. R. Kalden et al., “Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis,” Arthritis and Rheumatism, vol. 41, no. 9, pp. 1552–1563, 1998. View at Publisher · View at Google Scholar · View at Scopus
  18. F. B. Vincent, E. F. Morand, K. Murphy, F. Mackay, X. Mariette, and C. Marcelli, “Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective,” Annals of the Rheumatic Diseases, vol. 72, no. 2, pp. 165–178, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. K. Bendtzen, P. Geborek, M. Svenson, L. Larsson, M. C. Kapetanovic, and T. Saxne, “Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor infliximab,” Arthritis and Rheumatism, vol. 54, no. 12, pp. 3782–3789, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. D. Ternant, E. Ducourau, A. Perdriger et al., “Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis,” British Journal of Clinical Pharmacology, vol. 78, no. 1, pp. 118–128, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. D. Pascual-Salcedo, C. Plasencia, S. Ramiro et al., “Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis,” Rheumatology, vol. 50, no. 8, pp. 1445–1452, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. A. J. Yarur, M. J. Kubiliun, F. Czul et al., “Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy,” Clinical Gastroenterology and Hepatology, vol. 13, no. 6, pp. 1118–1124.e3, 2015. View at Publisher · View at Google Scholar · View at Scopus
  23. M. J. Hayes, A. C. Stein, and A. Sakuraba, “Comparison of efficacy, pharmacokinetics, and immunogenicity between infliximab mono- versus combination therapy in ulcerative colitis,” Journal of Gastroenterology and Hepatology, vol. 29, no. 6, pp. 1177–1185, 2014. View at Publisher · View at Google Scholar · View at Scopus